source
- FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapyThe FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…
- ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugA new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.